DOR BioPharma Announces $940,000 FDA Orphan Products Grant for Clinical Development of RiVax(TM) (Marketwire via Yahoo! Finance)
DOR BioPharma, Inc. announced today that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration has awarded a development grant for the further clinical evaluation of its vaccine for ricin toxin, RiVax(TM). The grant has been awarded to UT Southwestern Medical Center, one of the Company's academic partners in the development of RiVax(TM). The Principal Investigator ...

FDA sued over Provenge delay (Seattle Times)
The heated controversy over Dendreon's prostate-cancer drug Provenge has boiled over into the courtroom. A patient-advocacy group sued U...

Are Pharmaceutical Companies Investable? (Seeking Alpha via Yahoo! Finance)
George Gutowski submits: Can investors continue considering pharmaceuticals suitable for investment? Consider the Pharmaceutical ETF . A one year hold takes you from $75 to $78, approximately.